Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Swedish Orphan Biovitrum A/S
A/S
Active
CVR 19179079
Sorgenfrivej 17, 2800
Kongens Lyngby
Wholesale of pharmaceutical and medical goods
·
NACE 4646
Est. 1996 · 30 years old
9 employees
Monitor
Share
Denmark
/
Companies
/
Wholesale of pharmaceutical and medical goods
/
Swedish Orphan Biovitrum A/S
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Gross profit
DKK millions
41M
31M
21M
10M
0M
2021: 33M
33M
2021
2022: 23M (-30% vs 2021)
23M
-30%
2022
2023: 22M (-4% vs 2022)
22M
-4%
2023
2024: 21M (-5% vs 2023)
21M
-5%
2024
2025: 18M (-14% vs 2024)
18M
-14%
2025
EBITDA
DKK millions
6M
5M
3M
2M
0M
2021: 4M
4M
2021
2022: 4M (0% vs 2021)
4M
0%
2022
2023: 4M (0% vs 2022)
4M
0%
2023
2024: 5M (+25% vs 2023)
5M
+25%
2024
2025: 3M (-40% vs 2024)
3M
-40%
2025
Income statement
DKK thousands
Item
2025
2024
2023
2022
2021
Gross profit
18.018
20.724
22.183
23.486
32.623
Staff expenses
-14.677
-16.141
-17.941
-19.833
-28.710
EBITDA
3.340
4.583
4.242
3.653
3.912
Depreciation & amort.
-8
-8
-8
-9
-16
EBIT
3.332
4.575
4.234
3.644
3.896
Net financials
1.045
1.424
1.276
588
422
Profit before tax
4.377
5.999
5.510
4.231
4.318
Tax
1.108
1.428
1.323
1.058
969
Net profit
3.269
4.570
4.188
3.173
3.350
Balance sheet
DKK thousands
Item
2025
2024
2023
2022
2021
Total assets
44.080
40.743
36.485
32.145
33.718
Equity
39.496
36.227
31.656
27.469
24.295
Long-term debt
0
0
0
0
0
Short-term debt
4.584
4.517
4.829
4.676
9.423
Total debt
4.584
4.517
4.829
4.676
9.423
Financial ratios
5-year trend
EBITDA margin (of gross profit)
18,5 %
This company
2021
2025
Equity ratio
89,6 %
This company
38,2 %
Market median
This company
Market median
135% above market
2021
2025
Return on equity
8,3 %
This company
18,4 %
Market median
This company
Market median
55% below market
2021
2025
Net profit margin (of gross profit)
18,1 %
This company
2021
2025
Asset turnover (of gross profit)
0,41×
This company
2021
2025
Debt / equity
0,12×
This company
0,62×
Market median
This company
Market median
81% below market
2021
2025
Annual reports & filings
Annual report 2025
Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
View
PDF
More on Swedish Orphan Biovitrum A/S
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
